Skip to main content

Advertisement

Table 4 Association of the intrinsic subtypes with chemotherapy response across the various pathology-based groups

From: Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

  All patients Luminal A Luminal B HER2-enriched Basal-like P value*
  n pCR n pCR n pCR n pCR n pCR  
All subgroups 838 23 % 281 6 % 168 16 % 93 37 % 296 38 % <0.001
HR+/HER2– 451 12 % 239 5 % 143 15 % 25 16 % 44 36 % <0.001
HER2+ 76 34 % 16 0 % 12 33 % 36 42 % 12 58 % 0.011
HR–/HER2– (TN) 292 37 % 19 26 % 8 0 % 30 47 % 235 37 % 0.011
  1. *Likelihood ratio tests: adjusting clinical features: age, clinical stage, clinical nodal status and study cohort. Hormone receptors status and HER2 status were also included in “all subgroups”
  2. pCR, Pathological complete response; ER, Estrogen receptor; PR, Progesterone receptor
Back to article page